Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...